SEC Form 4 · accession 0001209191-17-026753
Forte Biosciences, Inc. · FBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas Jolly
Officer — EVP, Research & Pharm Devel
Period of report
Apr 12, 2017
Accepted (ET)
Apr 12, 2017 · 9:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419041
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $10.00 | Apr 12, 2017 | A | 14,492 | A | — | Apr 11, 2027 | Common Stock | 14,492 | 14,492 | D |
Explanation of responses
- F11/4th of the shares vest one year after 4/1/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/1/2017.